HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories, Inc. (OTC:IPXL) today announced that the Company has begun work to develop a next-generation carbidopa/levodopa product. The decision follows a meeting with the U.S. Food and Drug Administration (FDA) to address the Agency’s previously disclosed concerns over product nomenclature and the potential for medication errors that might result from confusion of the Company’s Vadova® tablets with other marketed forms of carbidopa/levodopa. Following an extensive analysis by the Company and discussion with the FDA, IMPAX has decided to cease work with the current formulation of the product.
